A substantial percentage of patients with inflammatory bowel disease (IBD) exhibit biologic treatment failure or loss of response over time. This article explores the effectiveness and safety of monoclonal antibodies targeting the IL-23 pathway in treating IBD; continued research is needed to address lingering questions regarding long-term safety and efficacy.
Are all the IL-23 blockers the same in inflammatory bowel disease? / Danese, Silvio; Peyrin-Biroulet, Laurent. - In: NATURE REVIEWS. GASTROENTEROLOGY & HEPATOLOGY. - ISSN 1759-5045. - 21:3(2024), pp. 138-139. [10.1038/s41575-023-00889-7]
Are all the IL-23 blockers the same in inflammatory bowel disease?
Danese, SilvioPrimo
;
2024-01-01
Abstract
A substantial percentage of patients with inflammatory bowel disease (IBD) exhibit biologic treatment failure or loss of response over time. This article explores the effectiveness and safety of monoclonal antibodies targeting the IL-23 pathway in treating IBD; continued research is needed to address lingering questions regarding long-term safety and efficacy.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
s41575-023-00889-7.pdf
solo gestori archivio
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Tutti i diritti riservati
Dimensione
902.9 kB
Formato
Adobe PDF
|
902.9 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
